tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:4AB Stock Latest News

AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
RatingsAbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
1h ago
ABBV
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
PremiumRatings
AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
4h ago
ABBV
AbbVie Reports Strong Q2 2025 Financial Results
PremiumCompany Announcements
AbbVie Reports Strong Q2 2025 Financial Results
8h ago
ABBV
Trump posts letters calling on drug company CEOs to lower prices
PremiumThe Fly
Trump posts letters calling on drug company CEOs to lower prices
18h ago
AZN
BMY
AbbVie says ‘fairly insulated’ from any tariff impacts this year
PremiumThe Fly
AbbVie says ‘fairly insulated’ from any tariff impacts this year
22h ago
ABBV
AbbVie sees Q3 adjusted EPS $3.24-$3.28, consensus $3.24
PremiumThe FlyAbbVie sees Q3 adjusted EPS $3.24-$3.28, consensus $3.24
22h ago
ABBV
AbbVie sees FY25 adjusted gross margin 84% of sales
Premium
The Fly
AbbVie sees FY25 adjusted gross margin 84% of sales
22h ago
ABBV
AbbVie says well positioned to deliver in FY25 and beyond
Premium
The Fly
AbbVie says well positioned to deliver in FY25 and beyond
22h ago
ABBV
Morning Movers: Roblox skyrockets following second quarter results
PremiumThe Fly
Morning Movers: Roblox skyrockets following second quarter results
23h ago
K
CI
AbbVie raises FY25 revenue view to $60.5B from ~$59.7B, consensus $60.01B
PremiumThe Fly
AbbVie raises FY25 revenue view to $60.5B from ~$59.7B, consensus $60.01B
23h ago
ABBV
AbbVie raises FY25 adjusted EPS view to $11.88-$12.08 from $11.67-$11.87
PremiumThe Fly
AbbVie raises FY25 adjusted EPS view to $11.88-$12.08 from $11.67-$11.87
1d ago
ABBV
AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
PremiumThe Fly
AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
1d ago
ABBV
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
PremiumThe FlyAbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
2d ago
ABBV
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
Premium
The Fly
AbbVie in discussions to buy Gilgamesh in $1B deal, Bloomberg reports
2d ago
ABBV
Notable companies reporting before tomorrow’s open
Premium
The Fly
Notable companies reporting before tomorrow’s open
2d ago
K
CI
AbbVie reports results from Phase 3 UP-AA clinical program
PremiumThe Fly
AbbVie reports results from Phase 3 UP-AA clinical program
2d ago
ABBV
AbbVie submits sNDA to the FDA for oral combination in lymphocytic leukemia
PremiumThe Fly
AbbVie submits sNDA to the FDA for oral combination in lymphocytic leukemia
3d ago
ABBV
AbbVie’s telisotuzumab adizutecan receives FDA orphan designation
PremiumThe Fly
AbbVie’s telisotuzumab adizutecan receives FDA orphan designation
4d ago
ABBV
AbbVie, IGI Therapeutics announce licensing agreement for ISB 2001
PremiumThe Fly
AbbVie, IGI Therapeutics announce licensing agreement for ISB 2001
22d ago
ABBV
AbbVie, Ichnos Glenmark Innovation enter exclusive licensing agreement
PremiumThe FlyAbbVie, Ichnos Glenmark Innovation enter exclusive licensing agreement
22d ago
ABBV
AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook
Premium
Ratings
AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook
22d ago
ABBV
AbbVie Buy Rating Supported by Strong Performance, Growth Prospects, and Strategic Positioning
Premium
Ratings
AbbVie Buy Rating Supported by Strong Performance, Growth Prospects, and Strategic Positioning
23d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >